FIELD: medicine.
SUBSTANCE: invention concerns medicine and biochemistry and concerns ways of identification of an inhibitor or the agonist of protein kinase IRS containing stages of introduction RKS-ζ in contact, at least, with one IRS peptide containing, at least, one site RKS-ζ-Ser-phosphorylation in the presence of, at least, one prospective inhibitor or an agonist, and b), degree measurements of phosphorylation site RKS-ζ-Ser-phosphorylation. And also peptide IRS-1 characterised by replacement of the rest 570 as a result of mutation on an alanine. The invention provides identification of inhibitors or agonists IRS for treatment of diabetes of type II.
EFFECT: identification of inhibitors or agonists IRS for treatment of diabetes of type II.
9 cl, 6 ex, 10 dwg
